Company intelligence / Profile preview

Infectious Diseases Research Institute

Seattle, Washington, United States

Ownership: Private
Employees: ~51
Development stage: Other

Overview

IDRI pioneered adjuvant and vaccine approaches for infectious diseases, most notably conducting the world’s first Phase 1 trials of a recombinant visceral leishmaniasis vaccine and advancing TB and Chagas programs to preclinical and early clinical evaluation. Diagnostics and adjuvant platforms have reached commercial and clinical use in multiple regions.

Therapeutic areas: Infectious Diseases
Modalities: VaccineSmall moleculeBiologicDiagnostic
Industry: Academic Hospital/University/Research

Partnerships

GSKBill & Melinda Gates FoundationWalter Reed Army Institute of ResearchAeras Global TB Vaccine FoundationPATH Malaria Vaccine InitiativeAmerican Leprosy MissionsFiocruzMSD Fellowship for Global HealthLilly

Beyond the preview

Go deeper on Infectious Diseases Research Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Infectious Diseases Research Institute.

Explore the full profile